Solid Dispersion Formulation for CFTR Potentiator Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cystic fibrosis, particularly those targeting the ΔF508 mutation in the CFTR gene, face challenges in achieving stable and bioavailable pharmaceutical compositions of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, which is a potent CFTR potentiator, to effectively treat patients with cystic fibrosis.
Innovation Solution
Development of pharmaceutical compositions comprising a solid dispersion of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, combined with excipients like hydroxypropylmethylcellulose, vinylpyrrolidone/vinyl acetate copolymer, and other additives, to enhance bioavailability and stability, formulated into tablets with specific dissolution profiles and hardness for effective administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional formulations of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide are used, then the compound can be administered to CF patients, but the bioavailability and stability of the compound are insufficient
Solution Approach 1:
The patent changes the physical state parameter of the compound from crystalline to amorphous form, which significantly improves bioavailability while maintaining stability through controlled solid dispersion in the tablet formulation
Solution Approach 2:
The patent creates a composite material system by combining the amorphous compound with specific excipients and formulating it as a solid dispersion in a tablet, enhancing both bioavailability and stability through the synergistic interaction of components
2Reliability
If the compound is formulated as a solid dispersion, then bioavailability and stability are improved, but the manufacturing complexity increases
Solution Approach 1:
The patent performs preliminary action by pre-formulating the amorphous compound as a solid dispersion with stabilizing excipients before tablet compression, which simplifies the overall manufacturing process while ensuring bioavailability and stability
Solution Approach 2:
The patent uses excipients as intermediary substances that facilitate the formation of stable solid dispersion, acting as mediators between the amorphous compound and the tablet matrix to enhance bioavailability without excessive manufacturing complexity
3Strength
If the tablet is compressed with high hardness, then the structural integrity is improved, but the dissolution rate may be reduced
Solution Approach 1:
The patent applies local quality by creating a tablet with optimized hardness in specific regions while maintaining overall structural integrity, allowing controlled dissolution rates in the amorphous compound regions while preserving tablet strength
Solution Approach 2:
The patent optimizes the hardness parameter within a specific range that balances structural integrity and dissolution rate, using controlled compression forces and formulation adjustments to achieve the optimal balance
Data Source
Figure 1
AI summary
The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention.